Logo image of DNAY

CODEX DNA INC (DNAY) Stock Fundamental Analysis

NASDAQ:DNAY - Nasdaq - US1920031010 - Common Stock - Currency: USD

1.3  +0.1 (+8.33%)

Fundamental Rating

2

DNAY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. DNAY may be in some trouble as it scores bad on both profitability and health. DNAY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DNAY has reported negative net income.
In the past year DNAY has reported a negative cash flow from operations.
DNAY Yearly Net Income VS EBIT VS OCF VS FCFDNAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 -10M -20M -30M

1.2 Ratios

The profitability ratios for DNAY are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DNAY Yearly ROA, ROE, ROICDNAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

DNAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNAY Yearly Profit, Operating, Gross MarginsDNAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

DNAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNAY has more shares outstanding than it did 1 year ago.
DNAY has a better debt/assets ratio than last year.
DNAY Yearly Shares OutstandingDNAY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 5M 10M 15M 20M 25M
DNAY Yearly Total Debt VS Total AssetsDNAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

DNAY has an Altman-Z score of -2.00. This is a bad value and indicates that DNAY is not financially healthy and even has some risk of bankruptcy.
DNAY has a Altman-Z score of -2.00. This is amonst the worse of the industry: DNAY underperforms 83.08% of its industry peers.
DNAY has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
DNAY has a Debt to Equity ratio of 0.37. This is comparable to the rest of the industry: DNAY outperforms 41.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z -2
ROIC/WACCN/A
WACC10.64%
DNAY Yearly LT Debt VS Equity VS FCFDNAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 20M -20M 40M 60M 80M

2.3 Liquidity

DNAY has a Current Ratio of 4.86. This indicates that DNAY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of DNAY (4.86) is comparable to the rest of the industry.
A Quick Ratio of 4.68 indicates that DNAY has no problem at all paying its short term obligations.
The Quick ratio of DNAY (4.68) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.86
Quick Ratio 4.68
DNAY Yearly Current Assets VS Current LiabilitesDNAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for DNAY have decreased strongly by -63.94% in the last year.
The Revenue has grown by 112.52% in the past year. This is a very strong growth!
EPS 1Y (TTM)-63.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.53%
Revenue 1Y (TTM)112.52%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%139.59%

3.2 Future

DNAY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.26% yearly.
Based on estimates for the next years, DNAY will show a very strong growth in Revenue. The Revenue will grow by 65.78% on average per year.
EPS Next Y-6.4%
EPS Next 2Y5.24%
EPS Next 3Y7.97%
EPS Next 5Y0.26%
Revenue Next Year106.09%
Revenue Next 2Y97.94%
Revenue Next 3Y85.04%
Revenue Next 5Y65.78%

3.3 Evolution

DNAY Yearly Revenue VS EstimatesDNAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
DNAY Yearly EPS VS EstimatesDNAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DNAY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNAY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNAY Price Earnings VS Forward Price EarningsDNAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNAY Per share dataDNAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.24%
EPS Next 3Y7.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNAY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CODEX DNA INC

NASDAQ:DNAY (1/3/2023, 8:00:01 PM)

1.3

+0.1 (+8.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-08 2022-11-08/amc
Earnings (Next)N/A N/A
Inst Owners0.08%
Inst Owner Change0%
Ins Owners28.32%
Ins Owner Change0%
Market Cap38.38M
Analysts84.44
Price Target6.63 (410%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.52%
Min EPS beat(2)4.82%
Max EPS beat(2)14.22%
EPS beat(4)2
Avg EPS beat(4)0.27%
Min EPS beat(4)-12.92%
Max EPS beat(4)14.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)24.03%
Min Revenue beat(2)23.47%
Max Revenue beat(2)24.59%
Revenue beat(4)3
Avg Revenue beat(4)9.32%
Min Revenue beat(4)-21.28%
Max Revenue beat(4)24.59%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.82
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS0.71
BVpS1.81
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 349.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.86
Quick Ratio 4.68
Altman-Z -2
F-Score3
WACC10.64%
ROIC/WACCN/A
Cap/Depr(3y)78.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-63.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.53%
EPS Next Y-6.4%
EPS Next 2Y5.24%
EPS Next 3Y7.97%
EPS Next 5Y0.26%
Revenue 1Y (TTM)112.52%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%139.59%
Revenue Next Year106.09%
Revenue Next 2Y97.94%
Revenue Next 3Y85.04%
Revenue Next 5Y65.78%
EBIT growth 1Y-78.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.29%
EBIT Next 3Y-12.51%
EBIT Next 5Y-7.76%
FCF growth 1Y-147.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.59%
OCF growth 3YN/A
OCF growth 5YN/A